PharmaSat
PharmaSat was a nanosatellite developed by NASA Ames Research Center which measured the influence of microgravity upon yeast resistance to an antifungal agent.The mission was designed to aid the development of medicines or techniques to enable long-term crewed space travel and habitation.The PharmaSat mission builds upon technology demonstrated by GeneSat-1, which used a CubeSat to study microfluidics and optics in the space environment.Based, like GeneSat-1, around a three-unit CubeSat platform; PharmaSat was designed to accomplish five functions in an autonomous free-flying platform:[4] PharmaSat was launched at 23:55 UTC on 19 May 2009 aboard a Minotaur I launch vehicle from Pad 0B at the Mid-Atlantic Regional Spaceport on Wallops Island.The primary ground station at SRI International in Menlo Park, California, transmitted mission data from the satellite to its operators, while a second station was located at Santa Clara University, whose Robotic Systems Laboratory was responsible for operating the satellite.